Previous research and studies have shown that patients taking cholesterol-reducing drugs had fewer colon polyps, which can lead to cancer if left untreated. However, those findings come largely from retrospective, observational studies originally designed to investigate lipid-lowering or cardiovascular endpoints in the short term rather than tumor endpoints.
This five-year, nationwide study will be the first randomized, prospective, placebo-controlled, double-blind study to evaluate the drug’s role in preventing colon cancer. The study will involve 1,740 patients.
Read the university news release about the rosuvastatin trial.
Read other coverage about GI studies:
– EUS-Guided Fine-Needle Biopsy Device Yields 85% Diagnostic Accuracy
– Mannitol Plus Simethicone Provides Improved Bowel Prep Before Capsule Endoscopy
– Study: Rate of Invasive CRC Low Among Endoscopically Resected Large Polyps
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.